Accordingly, the objective of the present study was to update the previous systematic literature review and conduct an NMA to estimate the relative treatment effect of iGlarLixi versus IDegAsp in populations with T2D inadequately controlled with basal insulin. This evidence concerns the gene INS and type 2 diabetes mellitus.